Amgen (AMGN.US) Q3 revenue and profit exceeded expectations and raised full-year guidance

The Zhitong Finance App learned that Amgen (AMGN.US) released the 2026 three-quarter report after the market on November 3: total revenue of US$10.365 billion, up 8% year on year, higher than the market estimate of about US$10.05 billion; non-GAAP earnings per share of US$6.45, up 14% year on year, significantly higher than the estimated US$5.77; GAAP earnings per share was 7.08 US dollars, up 19% year on year.

Growth products continued to grow: UPLIZNA's revenue was US$451 million, up 191% year on year; IMDELLTRA's revenue was US$406 million, up 128%; TEZSPIRE's revenue was US$538 million, up 43%; EVENITY's revenue was US$751 million, up 39%; and Repatha's revenue was US$1,085 million, up 37%.

Old varieties were significantly impacted by biosimilars: Prolia's revenue was US$632 million, a year-on-year decrease of 45%; XGEVA's revenue was US$288 million, a decrease of 47%; and Otezla's revenue was US$481 million, a decrease of 18%. Sales of a total of 17 products achieved double-digit growth during the quarter.

The company also raised its 2026 full-year guidance: total revenue was raised from the previous forecast of US$38.2 billion to US$39.4 billion to US$38.9 billion to US$39.7 billion; non-GAAP earnings per share were raised from US$22.30 to US$23.50 to US$22.90 to US$23.70.

Amgen's stock price declined after the market despite both performance and guidance exceeding expectations. As of press time, the stock was down 1.6% after the market.